Avelox ® - Moxifloxacin
Historical source. Current clinical review is incomplete. This monograph will be updated in the future.
Avelox ® - Moxifloxacin (opens in a new tab)Original source URL: https://globalrph.com/dilution/avelox-moxifloxacin/ | Retrieved 2026-11-04
Source dates, location and integrity
This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.
- Original source URL
- https://globalrph.com/dilution/avelox-moxifloxacin/ (opens in a new tab)
- Source date
- Not established in the retrieved source
- Retrieved
- 2026-11-04T19:46:06.217271+00:00
- Source location
- div.post-content
- Packaged content SHA-256
- f08b67968cc7e2e32fd103aaa17df4598032408678777f9ade9a0e3c55d43532
- Original response SHA-256
- ff5d59674e43a07ec5332ba64883ee90d0bdc87040dbe2d8d3c4c9a49b7ce14b
- Source body SHA-256
- 68ad29630b948aa7e4756cecc84ce4f6a4052f4eb8e3b433d054bcb7a62ebe62
Moxifloxacin (Avelox ®) |
|||||||||||||||||||||||||||||||||||||
| The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. | |||||||||||||||||||||||||||||||||||||
Usual Diluents |
|||||||||||||||||||||||||||||||||||||
| Not applicable - Premix Bags - 0.8% saline | |||||||||||||||||||||||||||||||||||||
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] |
|||||||||||||||||||||||||||||||||||||
| [ 400 mg ] [ 250 ml ] [ 1 hour ]
Premix Bags: AVELOX I.V. (moxifloxacin hydrochloride in sodium chloride injection) is available in ready-to-use 250 mL latex-free flexible bags containing 400 mg of moxifloxacin in 0.8% saline. NO FURTHER DILUTION OF THIS PREPARATION IS NECESSARY. |
|||||||||||||||||||||||||||||||||||||
Stability / Miscellaneous |
|||||||||||||||||||||||||||||||||||||
AVELOX I.V. should be administered by INTRAVENOUS infusion only. DOSAGE AND ADMINISTRATION: The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. For Complicated Intra-Abdominal Infections, therapy should be initiated with the intravenous formulation. When switching from intravenous to oral dosage administration, no dosage adjustment is necessary. Patients whose therapy is started with AVELOX I.V. may be switched to AVELOX Tablets when clinically indicated at the discretion of the physician.
Impaired Renal Function: No dosage adjustment is required in renally impaired patients, including those on either hemodialysis or continuous ambulatory peritoneal dialysis. Separate renal reference: Open Renal Dosing Master (opens in a new tab)Parenteral drug products should be inspected visually for particulate matter prior to administration. Samples containing visible particulates should not be used. Since the premix flexible containers are for single-use only, any unused portion should be discarded. Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Source: Bayer Pharmaceuticals. Avelox (moxifloxacin) [package insert]. West Haven, CT; 2007. |
|||||||||||||||||||||||||||||||||||||